Phase II Study of Sorafenib (Bay 43-9006) and Docetaxel in Metastatic Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2009
At a glance
- Drugs Docetaxel; Sorafenib
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.